Bausch + Lomb Receives Health Canada Medical Device Licence for VICTUS

VICTUS platform offers one of the largest arrays of licensed applications for femto-assisted cataract and refractive surgery Bausch + Lomb announced that its Victus™ Femtosecond Laser Platform was issued a Health Canada Medical Device Licence (MDL). The VICTUS Femtosecond Laser Platform, capable of supporting cataract and corneal procedures on a single platform, offers greater consistency and precision over manual cataract surgery techniques.   The Victus platform is one of the only femtosecond lasers in Canada with a licence for the creation of a corneal flap in patients undergoing LASIK surgery, anterior capsulotomy during cataract surgery, penetrating arcuate cuts/incisions in the cornea and laser-assisted lens fragmentation during cataract surgery. Bausch + Lomb Technolas (Technolas Perfect Vision GmbH) has been installing VICTUS platforms in leading surgery centers globally since it received CE mark in November 2011 and U.S. FDA clearance in July 2012.   "The Victus platform delivers major advancements in cataract and refractive surgery, allowing ophthalmic surgeons to perform multiple bladeless, sight-enhancing procedures on a single system," said Jonathan Abrams, commercial director for Bausch + Lomb Surgical, Canada. "We are committed to playing a leadership role in advancing femtosecond laser technology by working with ophthalmic industry leaders and professional societies alike. We look forward to introducing this technology in Canada, so that ophthalmic surgeons can experience its potential for themselves."   While current cataract surgery techniques achieve positive outcomes, the procedure relies on multiple manual steps, which creates variability. Early published data suggest that laser refractive cataract surgery (LRCS), as offered by the Victus platform, may allow physicians to create a more precise, controllable and centered capsulotomy (an incision in the capsular bag that allows access to the cataract-clouded natural lens). LRCS may also require less phaco energy and time during lens fragmentation, improve intraocular lens placement, and potentially enhance patient outcomes and experience.